Brent Kuenzi

Brent Kuenzi

Auto-generated profile, based on publicly available information

Brent Kuenzi

Division of Genetics, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in Cancer Cell
Verified
Journal Article
Closed access
BKBrent M. Kuenzi
Brent M. Kuenzi
JPJisoo Park
Jisoo Park
SFSamson H. Fong
Samson H. Fong
KSKyle S. Sanchez
Kyle S. Sanchez
JLJohn Lee
John Lee
TITrey Ideker
Trey Ideker

12 February 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MRMaria C. Ramello
Maria C. Ramello
IBIsmahène Benzaïd
Ismahène Benzaïd
BKBrent M. Kuenzi
Brent M. Kuenzi
MLMaritza Lienlaf-Moreno
Maritza Lienlaf-Moreno
WKWendy M. Kandell
Wendy M. Kandell
DADaniel Abate-Daga
Daniel Abate-Daga
The total length of CAR intracellular domains determines interactions with endogenous proteins to promote TCR signaling.

1 December 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
CKClaire E. Knezevic
Claire E. Knezevic
GWGabriela Wright
Gabriela Wright
LRLily L. Remsing Rix
Lily L. Remsing Rix
WKWoosuk Kim
Woosuk Kim
BKBrent M. Kuenzi
Brent M. Kuenzi
URUwe Rix
Uwe Rix

1 October 2021 in Science
Verified
Journal Article
Closed access
FZFan Zheng
Fan Zheng
MKMarcus R. Kelly
Marcus R. Kelly
DRDana J. Ramms
Dana J. Ramms
MHMarissa L. Heintschel
Marissa L. Heintschel
KTKai Tao
Kai Tao
TITrey Ideker
Trey Ideker
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV

16 August 2022 in Science Signaling
Verified
Journal Article
Closed access
LRLily L. Remsing Rix
Lily L. Remsing Rix
NSNatalia J. Sumi
Natalia J. Sumi
QHQianqian Hu
Qianqian Hu
BDBina Desai
Bina Desai
ABAnnamarie T. Bryant
Annamarie T. Bryant
URUwe Rix
Uwe Rix
Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in CAF-conditioned medium unexpectedly induced drug sensitivity in certain lung cancer cell lines. Gene expression and secretome analyses of CAFs and normal lung–associated fibroblasts (NAFs) revealed differential abundance of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs), which promoted or inhibited, respectively, signaling by the receptor IGF1R and the kinase FAK. Similar drug sensitization was seen in gefitinib-resistant, EGFR -mutant PC9GR lung cancer cells treated with recombinant IGFBPs. Conversely, drug sensitivity was decreased by recombinant IGFs or conditioned medium from CAFs in which IGFBP5 or IGFBP6 was silenced. Phosphoproteomics and receptor tyrosine kinase (RTK) array analyses indicated that exposure of PC9GR cells to CAF-conditioned medium also inhibited compensatory IGF1R and FAK signaling induced by the EGFR inhibitor osimertinib. Combined small-molecule inhibition of IGF1R and FAK phenocopied the CAF-mediated effects in culture and increased the antitumor effect of osimertinib in mice. Cells that were osimertinib resistant and had MET amplification or showed epithelial-to-mesenchymal transition also displayed residual sensitivity to IGFBPs. Thus, CAFs promote or reduce drug resistance in a context-dependent manner, and deciphering the relationship between the differential content of CAF secretomes and the signaling dependencies of the tumor may reveal effective combination treatment strategies.

11 November 2013 in ACS Chemical Biology
Verified
Journal Article
Closed access
LRLily L. Remsing Rix
Lily L. Remsing Rix
BKBrent M. Kuenzi
Brent M. Kuenzi
YLYunting Luo
Yunting Luo
ERElizabeth Remily-Wood
Elizabeth Remily-Wood
FKFumi Kinose
Fumi Kinose
URUwe Rix
Uwe Rix